degruyter.com uses cookies to store information that enables us to optimize our website and make browsing more comfortable for you. To learn more about the use of cookies, please read our privacy policy.OK
Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Metallo-Drugs: Development and Action of Anticancer Agents

Ed. by Sigel, Astrid / Sigel, Helmut / Freisinger, Eva / Sigel, Roland K.O.

With contrib. by Riddell, Imogen / Lippard, Stephen J. / Brabec, Victor / Kasparkova, Jana / Menon, Vijay / Farrell, Nicholas P. / Venkatesh, V. / Sadler, Peter J. / Gorle, Anil K. / Peterson, Erica J. / Berners-Price, Susan / Alessio, Enzo / Messori, Luigi / Babak, Maria V. / Ang, Wee Han / Casini, Angela / Sun, Raymond Wai-Yin / Ott, Ingo / Tshuva, Edit / Miller, Maya / Crans, Debbie / Yan, Lining / Haase, Allison / Yang, Xiaogai / Chitambar, Christopher / Cardo, Lucia / Hannon, Michael John / Vilar, Ramon / Sullivan, Matthew P. / Holtkamp, Hannah U. / Hartinger, Christian G. / Schatzschneider, Ulrich / Thévenod, Frank / Denoyer, Delphine / Clatworthy, Sharnel A. S. / Cater, Michael / Ziliotto, Silvia / Ogle, Olivia / Taylor, Kathryn M.

Series:Metal Ions in Life Sciences 18

eBook (PDF)
Publication Date:
February 2018
Copyright year:
2018
ISBN
978-3-11-047073-4
See all formats and pricing

16. Copper Complexes in Cancer Therapy

Denoyer, Delphine / Clatworthy, Sharnel A. S. / Cater, Michael A.

Abstract

Copper homeostasis is tightly regulated in both prokaryotic and eukaryotic cells to ensure sufficient amounts for cuproprotein biosynthesis, while limiting oxidative stress production and toxicity. Over the last century, copper complexes have been developed as antimicrobials and for treating diseases involving copper dyshomeostasis (e.g., Wilson’s disease). There now exists a repertoire of copper complexes that can regulate bodily copper through a myriad of mechanisms. Furthermore, many copper complexes are now being appraised for a variety of therapeutic indications (e.g., Alzheimer’s disease and amyotrophic lateral sclerosis) that require a range of copper-related pharmacological affects. Cancer therapy is also drawing considerable attention since copper has been recognized as a limiting factor for multiple aspects of cancer progression including growth, angiogenesis, and metastasis. Consequently, ‘old copper complexes’ (e.g., tetrathiomolybdate and clioquinol) have been repurposed for cancer therapy and have demonstrated anticancer activity in vitro and in preclinical models. Likewise, new tailor-made copper complexes have been designed based on structural and biological features ideal for their anticancer activity. Human clinical trials continue to evaluate the therapeutic efficacy of copper complexes as anticancer agents and considerable progress has been made in understanding their pharmacological requirements. In this chapter, we present a historical perspective on the main copper complexes that are currently being repurposed for cancer therapy and detail several of the more recently developed compounds that have emerged as promising anticancer agents. We further provide an overview of the known mechanisms of action, including molecular targets and we discuss associated clinical trials.

Citation Information

Delphine Denoyer, Sharnel A. S. Clatworthy, Michael A. Cater (2018). 16. Copper Complexes in Cancer Therapy. In Astrid Sigel, Helmut Sigel, Eva Freisinger, Roland K.O. Sigel (Eds.), Metallo-Drugs: Development and Action of Anticancer Agents (pp. 469–506). Berlin, Boston: De Gruyter. https://doi.org/10.1515/9783110470734-022

Book DOI: https://doi.org/10.1515/9783110470734

Online ISBN: 9783110470734

© 2018 Walter de Gruyter GmbH, Berlin/Munich/BostonGet Permission

Comments (0)

Please log in or register to comment.
Log in